Purpose: MCF-7 (ER+, WTP53) and MDA-MB-231 (ER Met, Mutant P53) Caffeic Acid Phenethyl Ester (CAPE) and DNA Methyl Transferase Inhibitor (DNMTi) in breast cancer cell lines of Zebularine (ZEB) single and combined application of TP53, caspase-9, caspase 8 and caspase-3 genes as a result of the use of single and combined drug methylation profiles are aimed to be evaluated by specific PCR method. Material-Metods: In the MCF-7 and MDA-MB-231 breast cancer cell lines, MTT test and survival analysis were performed as a result of single and combined application of CAPE and Zebularine and Methylation Specific PCR was performed to examine the methylation of caspase-3, caspase-8, caspase-9 and TP53 genes. Results: According to the results of 24-hour drug administration, the IC 50 for the MCF-7 cell line was determined as 200 μM, for CAPE 40 μM and for the combined values of 50 μM ZEB + 5 μM CAPE. The effects of caspase-3, caspase-8, caspase-9 and TP53 genes on the methylation level of ZEB, CAPE and ZEB + CAPE drug combination were determined by using bisulfite modified DNAs in MCF-7 and MDA-MB-231 cell lines. Discussion: In the MCF-7 cell line, the 120 µM ZEB viability rate was 51%, and the viability of The 80 µM ZEB concentration was found to be closely related to the unmethylated status of the TP53 gene. These results obtained with 50 µM ZEB + 5 µM CAPE application were found to be related to the methylated-unmetylated status of the TP53 gene in half (50%). For the caspase-9 gene of MDA-MB-231 cells, 80 µM ZEB concentration was found to be associated with unmetylated status. The effective use of drugs with low concentrations of the drug dose provides a more appropriate approach in terms of treatment.
Introduction
Breast cancer is a common type of cancer and, despite improvements in its treatment, it is still considered to be the main cause of death in women [1] .
Studies have shown that breast cancer is a heterogeneous tumor that responds differently to treatments. Breast cancer is caused by the accumulation of genetic and epigenetic events. Most of the epigenetic modifications are reversible events that target the gene sequence after transcription and the inhibition of these mechanisms may be advantageous in the treatment of breast cancer [2] . DNA methylation is an important epigenetic modification that is most studied and involved in the regulation of many cell processes beyond the DNA sequence level [3] . Cancer cells often exhibit abnormally high DNA methylation at gene-specific CpG-rich promoter sites [4] . DNA methylation is controlled by DNA methyl transferase (DNMT), an enzyme that catalyses the transfer of a methyl group from S-adenosyl-1-methionine to the 5-position of cytosines in the CpG nucleotide. DNMT overexpression was detected in various malignancies, including lung, prostate, and colorectal tumors [3] [4] . Since DNA methylation is a reversible biochemical process, and DNMT inhibitors are not specific to cancer type, DNMT may be a viable target in cancer treatment, since it can be used in the treatment of various cancers [5] . By inhibiting DNMTs, genes that may be silenced by DNA methylation during the carcinogenic process can be reactivated and the non-carcinogenic state of the cell can be regenerated [6] .
Because of this feature, DNA methylation changes are believed to be an alternative pathway for cancer and have the potential to be diagnostic markers that can be used in the clinical context [7] .
Zebularine (ZEB), a novel DNMT inhibitor, is a sitidine analogue [8] deaminase inhibitor to prevent deamination of nucleoside analogs. Zebularine is a versatile starting material for the synthesis of complex nucleosides and is a mechanism based on mechanism DNA cytosine methyl transferase inhibitor [10] . The mechanism of action of ZEB as a DNMTi is its incorporation into DNA after its phosphorylation to the diphosphate level and its conversion to a deoxynucleotide. Unlike other DNMTi, zebularine is less toxic for breast cancer cell lines and there are antimitogenic and angiostatic effects of ZEB. It has been
shown that ZEB has antitumor activity by stimulating apoptosis and has an effect of inhibiting cell proliferation [2] . Caffeic acid phenethyl ester (CAPE) is polyphenol, a component of honeybee propolis. CAPE has a number of important biological activities including anti-bacterial, antiviral, antifungal, antioxidant, anti-inflammatory and anticancer properties [11] . CAPE has been supported by studies on cell cycle progression, cell proliferation, cell cycle arrest and apoptosis in many cancer models (colon, lung, pancreatic).
CAPE inhibits the activity of cancer cells using nuclear transcription factor NF-kB. Studies have shown that NF-kB may be one of the most important factors in oncogenesis and cancer progression. In addition, CAPE is capable of exhibiting different toxicity to tumor models without affecting normal cells [12] .
Drug metabolism times of those two kinds of DNA methyl transferase inhibitors CAPE and ZEB are 24 to 96 hours.
Apoptosis (programmed cell death) is a critical obstacle to tumorigenesis.
Proteins such as calcium, ceramide, Bcl-2 family, P53, caspases, cytochrome-c and mitochondria serve in the regulation of apoptosis. Caspases are a cysteine protease family and function as central regulators of cell death. TP53 is mutated in most cancers and mutated in 30% -50% of diagnosed breast tumors.
Chemotherapeutic agents may affect many effector and regulatory elements of the process of apoptosis. Several studies have shown that chemopreventive agents induce apoptosis in various cancer cells by affecting multiple proteins involved in programmed cell death. In accordance with the need for new compounds with both effective antitumor effect and high cancer cell selectivity and low normal cell toxicity, recently some compounds have increased the need for natural compounds to inhibit cancer cell growth [13] .
In the first stage of this study, the DNA metabolite transferase inhibitor 
Determination of the Effects of Applied Drugs on Epigenetics

DNA Isolation
Total DNA isolation from breast cancer cells was performed to determine the effect of applied drugs on methylation and total DNA concentrations isolated were measured in nanodrop device. (Nanodrop, Shimadzu Corporation, BioSpec-nano, Japan).
Bisulfite Modification and Methylation Specific PCR (MSP)
It is the process of converting unmetylated cytosine residues to uracil without any change in methylated cytosines. Zymo EZ DNA Methylated-GoldTM kit (D5005, Zymo Research Corp., Orange, CA) was used for the bisulfite conversion of genomic DNA. The bisulfite transformed DNA was used as a template and MSP method was applied to determine the methylation status of the genes that obtained significant results, especially caspase 3, caspase 8 and caspase 9 ( Genes Primers
Results
The Effect of Combined Application of ZEB, CAPE and ZEB + CAPE on Cell Viability in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines
In 
The Effect of CAPE, ZEB, CAPE + ZEB Combination on Cell Survival in MCF-7 and MDA-MB-231 Breast Cancer Cell Line
In order to demonstrate the effect of CAPE (20 - The counts showed that cell growth was decreased in time depending on time in both cell lines. When the data were examined, it was seen that combined therapy was effective in both cell lines without producing cytotoxic effect The methylation profile evaluation of the respective genes on 2 different cell lines used in the study is shown in Figure 6 (p < 0.5).
As a result, it was concluded that the combined treatment in MCF-7 breast cancer cell lines was highly effective. However, it has been observed that the same doses of drugs in different genes may cause different methylation conditions. For example, the CAPE 80 μM dosage is closely related to the unmethylated condition in caspase-8 and caspase-9 in TP53 and caspase-3. On the other hand, in combination applications, the effect is constant and half is associated with methylation-unmethylation. This result is important in terms of the efficiency of the treatment.
In general, drugs administered on MDA-MB-231 cell lines did not have a methylation effect on caspase-8, but stimulation was carried out via the intrinsic pathway, which is the internal signaling pathway, or via a different signaling pathway. In addition, it is seen that the combined drug application is successful. 
Discussion
Although the monotherapy approach is still a very common treatment for many different types of cancer, this method is generally considered less effective than a combined therapy approach. Combined therapy can prevent toxic effects on normal cells and can also produce cytotoxic effects on cancer cells. Zebularine is a DNMT inhibitor that exhibits anti-tumor effect against various types of cancer. CAPE significantly affects the viability of breast cancer cells and increases the effect of standard anti-cancer drugs, suggesting the potential role of bioactive compounds in chemotherapy. In this study, it was aimed to investigate the relationship between apoptosis induced by caspases and epigenetic regulation of the anticancer and antiproliferative effects of CAPE, ZEB and CAPE + ZEB combined applications in MCF-7 and MDA-MB-231 cell lines and the combined application of CAPE, ZEB single and CAPE + ZEB in MCF-7 and Journal of Cancer Therapy MDA-MB-231 cell lines. The combined use of CAPE and ZEB drugs was applied for the first time in this study.
In this study, it was determined that single and combined application of ZEB and CAPE in two breast cancer cell lines reduced cell proliferation and induced apoptotic pathway (Figures 2-4) . MDA-MB-231 breast cancer cell line MCF-7 cell line compared to MDA-MB-231 cell line because of the mutant TP53 gene is more susceptible to cytotoxic agents. In addition, one of the reasons for MCF-7 cells being less susceptible to the effect of ZEB is the low rate of growth in the cells due to the zebularine.
Billam et al. (2010) in his study showed that high concentrations of ZEB may cause cytotoxicity in cells, while inhibiting cell proliferation. Billam et al. found that ZEB, which is a DNMT inhibitor, is less toxic in many cell lines compared to other DNTMs. Therefore, it is thought that ZEB can be used alone or in combination with DNMT inhibitors such as other 5-aza-dC for prolonged administration [14] . In a study by Napso et al. (SCC-9 and SCC-25), 50 veM and 48
hours ZEB were applied in head and neck cancer cells. It has been shown that ZEB plays an important role in the induction of apoptosis due to time and reduces cell proliferation by approximately 20% [15] . Kaishan et al. (2016) found that ZEB inhibited proliferation of osteosarcoma cells and disrupted the interaction between DNMT1-G9a and increased apoptosis by suppressing methylation of the ARHI gene [16] .
The combination of 50 μM ZEB + 5 μM CAPE combined dose of 50 μM in MCF-7 breast cancer cells after the 24-hour administration showed that the combined efficacy could be used effectively (Figure 3(a) ). Rzepecka et al. (2017) found that IC 50 values of CAPE MDA-MB-231 cells were found to be 27.84 50 M for 24-hour incubation and 15.84 MM for 48 hours [17] . CAPE has been confirmed to be cytotoxic for cells similar to that in this study. The nuclear factor of CAPE showed that it inhibited NFKB1. They also studied CAPE to confirm that death-inducing receptors were clustered. They demonstrated that CAPE induces apoptosis and that Fas death-inducing receptors are harvested by a Fas-L independent mechanism in MCF-7 cells [18] . Given the similarity in structures between CAPE and estrogen, CAPE may be more effective than MDA-MB-231 (estrogen receptor-negative) cells in T47D
(estrogen receptor positive) cells. According to this information, we can say that CAPE is more effective than MDA-MB-231 cells in MCF-7 cells that we use in our study.
The data obtained in combination with CAPE and DNMT inhibitor ZEB, which is known to be effective in apoptotic pathway in accordance with the literature, has been found to be effective in reducing the cytotoxicity caused by drugs. CAPE + ZEB combined drug therapy is thought to be promising for new treatments. This difference between the two cell lines makes MDA-MB-231 cells more susceptible to cytotoxicity of the drug because ER is negative. According to the data obtained in the literature, it was revealed that high dose concentrations of ZEB caused cytotoxic effects in the cell.
Recent studies have shown that the incidence of P53 mutations is different between the various types of cancer (~% 96 for serous ovarian cancer, <10% for thyroid cancer). The incidence of P53 mutation for primary breast carcinomas is 18% -25% [23] . He stated that CAPE plays an important role in apoptosis and cell cycle. It has also been found in several studies that CAPE can reduce the expression of the MDR-1 gene and thus increase the susceptibility of cancer cells to chemotherapy, as the high expression and activity of the MDR1 gene causes the cancer cells to become resistant to treatment with many agents [24] [25].
The application of CAPE and ZEB to breast cancer cell lines induces p53 tumor suppressive activity and thus leads to apoptosis sensitivity of the cancer cell. In our study, 20 μM CAPE concentration was found to be associated with methylation of TP53 in MCF-7 cell lines (Figure 6(a) ). The low dose ZEB concentration (80 µM) was found to increase the expression of the TP53 gene according to the high dose ZEB concentration (120 µM) (Figure 6(a) ). These results obtained with 50 µM ZEB + 5 µM CAPE application were found to be related to the methylated and unmethylated status of the TP53 gene in half ( Figure 6(a) ). MDA-MB-231 breast cancer cell line with increasing the CAPE dose of the TP53 gene has been found to change from methylated to unmethylated state (p < 0.05) (Figure 6(b) ). In a study conducted by You et al.
(2014), it has been shown that TP53 activity, which is a tumor suppressor gene, has been increased in ZEB administered lung cancer cell line A549 and HPF cells [25] . In accordance with the literature, the data showed that the TP53 gene, µM CAPE on the caspase 9 gene was found to be more effective than the Zebularine, as opposed to the CAPE effect and a more efficient unmetilized condition, which was thought to be associated with a more active apoptotic stimulation and the efficacy of the combined application on the cells was higher (Figure 6 showed that combined application with CAPE was 1.3 times more effective in the effectiveness of caspase-3 compared to drug administration alone [31] . Our study, which is supported by literature research, is to suggest that interactions of ZEB + CAPE combined drug therapy are more effective in cell proliferation and apopototic mechanism compared to ZEB and CAPE alone application to MDA-MB231 breast cancer cell line cells (Figure 3(b) ). The explanation of the association of CAPE with apoptosis and the similarity of caspase gene induction processes in different cancer cell lines has been supported by literature studies.
In general, it has been observed that the drugs administered in MDA-MB-231 cell lines have no effect on the methylene status via caspase-8, according to the results obtained, it was thought that the stimulation was carried out via the intrinsic pathway, which is the internal signaling path, or through a different signaling pathway affected. It can also be said that the combined drug application is successful. Effective combination with low concentrations of dose ratios in the combined drug provides a more appropriate approach in terms of treatment.
Based on our findings, it was observed that CAPE, ZEB and CAPE + ZEB combined drugs inhibited MCF-7 and MDA-MB-231 cell proliferation and were more effective in apoptosis mechanism. It has been shown that the apoptosis-related genes were unmethylated and significantly increased apoptosis 
